|
1
|
Akbar S and Alorainy MS: The current
status of β-blockers' use in the management of hypertension. Saudi
Med J. 35:1307–1317. 2014.PubMed/NCBI
|
|
2
|
Pemberton P, Veenith T, Snelson C and
Whitehouse T: Is it time to beta block the septic patient? Biomed
Res Int. 2015:4243082015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loftus TJ, Efron PA, Moldawer LL and Mohr
AM: β-blockade use for traumatic injuries and immunomodulation: A
review of proposed mechanisms and clinical evidence. Shock.
46:341–351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nwabudike LC and Tatu AL: Response to
chronic exposure to tetracyclines and subsequent diagnosis for
non-melanoma skin cancer in a large Mid-Western US population. J
Eur Acad Dermatol Venereol. 32:e1592018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tatu AL and Nwabudike LC: Bullous
reactions associated with COX-2 inhibitors. Am J Ther.
24:e477–e480. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gheorghe I, Tatu AL, Lupu I, Thamer O,
Cotar AI, Pircalabioru GG, Popa M, Cristea VC, Lazar V and
Chifiriuc MC: Molecular characterization of virulence and
resistance features in Staphylococcus aureus clinical
strains isolated from cutaneous lesions in patients with drug
adverse reactions. Rom Biotechnol Lett. 22:12321–12327. 2017.
|
|
7
|
Happle R and Kluger N: Koebners sheep in
Wolf's clothing: does the isotopic response exists as a distinct
phenomenon? J Eur Acad Dermatol Venereol. 32:542–543. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gambichler T, Rüddel I, Hessam S, Bechara
FG, Stockfleth E and Schmitz L: Altered epigenetic pathways and
cell cycle dysregulation in healthy appearing skin of patients with
koebnerized squamous cell carcinomas following skin surgery. J Eur
Acad Dermatol Venereol. 32:1485–1491. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tantu M, Belu E, Bobescu E, Armean SM,
Armean P, Constantin MM and Domnariu CD: Role of angiotensin
converting enzyme (ACE) inhibitors in hypertension and
cardiovascular protection management. Farmacia. 62:443–451.
2014.
|
|
10
|
Chen L and Tsai TF: The role of β-blockers
in dermatological treatment: A review. J Eur Acad Dermatol
Venereol. 32:363–371. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sivamani RK, Lam ST and Isseroff RR: Beta
adrenergic receptors in keratinocytes. Dermatol Clin. 25:643–653.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yilmaz MB, Turhan H, Akin Y, Kisacik HL
and Korkmaz S: Beta-blocker-induced psoriasis: A rare side effect -
a case report. Angiology. 53:737–739. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Brien M and Koo J: The mechanism of
lithium and beta-blocking agents in inducing and exacerbating
psoriasis. J Drugs Dermatol. 5:426–432. 2006.PubMed/NCBI
|
|
14
|
Tsankov N, Angelova I and Kazandjieva J:
Drug-induced psoriasis. Recognition and management. Am J Clin
Dermatol. 1:159–165. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sehgal VN, Dogra S, Srivastava G and
Aggarwal AK: Psoriasiform dermatoses. Indian J Dermatol Venereol
Leprol. 74:94–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fry L and Baker BS: Triggering psoriasis:
The role of infections and medications. Clin Dermatol. 25:606–615.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Halevy S and Livni E: Psoriasis and
psoriasiform eruptions associated with propranolol - the role of an
immunological mechanism. Arch Dermatol Res. 283:472–473. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim GK and Del Rosso JQ: Drug-provoked
psoriasis: is it drug induced or drug aggravated?: understanding
pathophysiology and clinical relevance. J Clin Aesthet Dermatol.
3:32–38. 2010.PubMed/NCBI
|
|
19
|
Shaw SM, Coppinger T, Waywell C, Dunne L,
Archer LD, Critchley WR, Yonan N, Fildes JE and Williams SG: The
effect of beta-blockers on the adaptive immune system in chronic
heart failure. Cardiovasc Ther. 27:181–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wahle M, Krause A, Pierer M, Hantzschel H
and Baerwald CG: Immunopathogenesis of rheumatic diseases in the
context of neuroendocrine interactions. Ann NY Acad Sci.
966:355–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eyre S, Bowes J, Potter C, Worthington J
and Barton A: Association of the FCRL3 gene with rheumatoid
arthritis: A further example of population specificity? Arthritis
Res Ther. 8:R1172006. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lubahn CL, Schaller JA, Bellinger DL,
Sweeney S and Lorton D: The importance of timing of adrenergic drug
delivery in relation to the induction and onset of adjuvant-induced
arthritis. Brain Behav Immun. 18:563–571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Härle P, Möbius D, Carr DJ, Schölmerich J
and Straub RH: An opposing time-dependent immune-modulating effect
of the sympathetic nervous system conferred by altering the
cytokine profile in the local lymph nodes and spleen of mice with
type II collagen-induced arthritis. Arthritis Rheum. 52:1305–1313.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan X and Wang I: β2 Adrenergic receptor
on T lymphocytes and its clinical implications. Prog Nat Sci.
19:17–23. 2009. View Article : Google Scholar
|
|
25
|
Tatu AL and Nwabudike LC:
Metoprolol-associated onset of psoriatic arthropathy. Am J Ther.
24:e370–e371. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Newman BR and Schultz LK:
Epinephrine-resistant anaphylaxis in a patient taking propranolol
hydrochloride. Ann Allergy. 47:35–37. 1981.PubMed/NCBI
|
|
27
|
Nassiri M, Babina M, Dölle S, Edenharter
G, Ruëff F and Worm M: Ramipril and metoprolol intake aggravate
human and murine anaphylaxis: Evidence for direct mast cell
priming. J Allergy Clin Immunol. 135:491–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van Beek LM, de Keizer RJ, Polak BCP,
Elzenaar PR, van Haeringen NJ and Kijlstra A: Incidence of ocular
side effects of topical β blockers in the Netherlands. Br J
Ophthalmol. 84:856–859. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheong HI, Johnson J, Cormier M and
Hosseini K: In vitro cytotoxicity of eight β-blockers in human
corneal epithelial and retinal pigment epithelial cell lines:
Comparison with epidermal keratinocytes and dermal fibroblasts.
Toxicol In Vitro. 22:1070–1076. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schallreuter KU: Beta-adrenergic blocking
drugs may exacerbate vitiligo. Br J Dermatol. 132:168–169. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu CS, Yu HS, Chang HR, Yu CL, Yu CL and
Wu BN: Cutaneous blood flow and adrenoceptor response increase in
segmental-type vitiligo lesions. J Dermatol Sci. 23:53–62. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tatu AL and Ionescu MA: Multiple
autoimmune syndrome type III-thyroiditis, vitiligo and alopecia
areata. Acta Endo Buc. 13:124–125. 2017. View Article : Google Scholar
|
|
33
|
Muramatsu K, Nomura T, Shiiya C, Nishiura
K and Tsukinaga I: Alopecia induced by timolol eye-drops. Acta Derm
Venereol. 97:295–296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Botchkarev VA, Peters EM, Botchkareva NV,
Maurer M and Paus R: Hair cycle-dependent changes in adrenergic
skin innervation, and hair growth modulation by adrenergic drugs. J
Invest Dermatol. 113:878–887. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lewis RV and Lofthouse C: Adverse
reactions with beta-adrenoceptor blocking drugs. An update. Drug
Saf. 9:272–279. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fraunfelder FT, Meyer SM and Menacker SJ:
Alopecia possibly secondary to topical ophthalmic β-blockers. JAMA.
263:1493–1494. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Richards S: Cutaneous side-effects of
beta-adrenergic blockers. Australas J Dermatol. 26:25–28. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shelley ED and Shelley WB: Alopecia and
drug eruption of the scalp associated with a new beta-blocker,
nadolol. Cutis. 35:148–149. 1985.PubMed/NCBI
|
|
39
|
England JR and England JD: Alopecia and
propranolol therapy. Aust Fam Physician. 11:225–226.
1982.PubMed/NCBI
|
|
40
|
Hilder RJ: Propranolol and alopecia.
Cutis. 24:63–64. 1979.PubMed/NCBI
|
|
41
|
Martin CM, Southwick EG and Maibach HI:
Propranolol induced alopecia. Am Heart J. 86:236–237. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bodmer M, Egger SS, Hohenstein E,
Beltraminelli H and Krähenbühl S: Lichenoid eruption associated
with the use of nebivolol. Ann Pharmacother. 40:1688–1690. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meyer S, Burgdorff T, Szeimies RM, Vogt T,
Landthaler M and Karrer S: Management of erosive lichen planus with
topical tacrolimus and recurrence secondary to metoprolol. J Eur
Acad Dermatol Venereol. 19:236–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brănișteanu DE, Pintilie A, Dimitriu A,
Cerbu A, Ciobanu D, Oanţă A and Tatu AL: Clinical, laboratory and
therapeutic profile of lichen planus. Rev Med Chir Soc Med Nat
Iasi. 121:25–32. 2017.(In Romanian).
|
|
45
|
Lage D, Juliano PB, Metze K, de Souza EM
and Cintra ML: Lichen planus and lichenoid drug-induced eruption: A
histological and immunohistochemical study. Int J Dermatol.
51:1199–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brănişteanu DE, Brănişteanu DC, Stoleriu
G, Ferariu D, Voicu CM, Stoica LE, Căruntu C, Boda D,
Filip-Ciubotaru FM, Dimitriu A, et al: Histopathological and
clinical traps in lichen sclerosus: A case report. Rom J Morphol
Embryol. 57 (Suppl 2):817–823. 2016.PubMed/NCBI
|
|
47
|
Tatu AL and Nwabudike LC: The treatment
options of male genital lichen sclerosus et atrophicus: Treatments
of Genital Lichen Sclerosus Conference. 14th National Congress of
Urogynecology (Urogyn) Location: Eforie, Romania Date: Sep 07-09,
2017, . Proceedings of the 14th National Congress of Urogynecology
and the National Conference of the Romanian Association for the
Study of Pain. 262–264. 2017.
|
|
48
|
Aslan AN, Güney MC, Akçay M, Keleş T and
Bozkurt E: Lichenoid type cutaneous hyperpigmentation induced by
nebivolol. Turk Kardiyol Dern Ars. 45:268–270. 2017.PubMed/NCBI
|
|
49
|
Schmutz JL, Houet C, Trechot P, Barbaud A
and Gillet-Terver MN: Sweating and beta-adrenoceptor antagonists.
Dermatology. 190:861995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shields SA, MacDowell KA, Fairchild SB and
Campbell ML: Is mediation of sweating cholinergic, adrenergic, or
both? A comment on the literature. Psychophysiology. 24:312–319.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lama PJ: Systemic adverse effects of
beta-adrenergic blockers: An evidence-based assessment. Am J
Ophthalmol. 134:749–760. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ali FR, Shackleton DB, Kingston TP and
Williams JD: Occupational exposure to propranolol: A rarely
recognised cause of allergic contact dermatitis. Int J Occup Med
Environ Health. 28:639–640. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jappe U, Uter W, Menezes de Pádua CA,
Herbst RA and Schnuch A: Allergic contact dermatitis due to
beta-blockers in eye drops: A retrospective analysis of multicentre
surveillance data 1993–2004. Acta Derm Venereol. 86:509–514. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tatu AL: Topical steroid induced facial
rosaceiform dermatitis. Acta Endo (Buc). 12:232–233. 2016.
View Article : Google Scholar
|
|
55
|
Tatu AL, Ionescu MA, Clatici VG and
Cristea VC: Bacillus cereus strain isolated from Demodex
folliculorum in patients with topical steroid-induced
rosaceiform facial dermatitis. An Bras Dermatol. 91:676–678. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tatu AL, Ionescu MA and Nwabudike LC:
Contact allergy to topical mometasone furoate confirmed by
rechallenge and patch test. Am J Ther. 25:e497–e498. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tatu AL and Clătici V: Some correlations
between the clinical and dermoscopic features of steroid induced
facial dermatitis. J Am Acad Dermatol. 72:912015. View Article : Google Scholar
|
|
58
|
Miyamoto D, Maruta CW, Santi CG,
Zoroquiain P, Dias AB, Mansure JJ, Burnier MN Jr and Aoki V:
Exploring the in situ expression of vascular endothelial growth
factor and endoglin in pemphigus foliaceus variants and pemphigus
vulgaris. J Eur Acad Dermatol Venereol. Feb 28–2018.(Epub ahead of
print). doi: 10.1111/jdv.14903. View Article : Google Scholar
|
|
59
|
Abdelmaksoud A and Vestita M:
Beta-blockers for treatment of autoimmune blistering dermatosis. J
Eur Acad Dermatol Venereol. May 6–2018.(Epub ahead of print). doi:
10.1111/jdv.15054. View Article : Google Scholar
|
|
60
|
Prabha N, Chhabra N and Arora R:
Beta-blockers in dermatology. Indian J Dermatol Venereol Leprol.
83:399–407. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Manu P and Rogozea LM: Propranolol for
angina pectoris. Am J Ther. 23:e1285–e1286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bilewicz-Stebel M, Miziołek B,
Bergler-Czop B and Stańkowska A: Drug-induced subacute cutaneous
lupus erythematosus caused by a topical beta blocker - timolol.
Acta Dermatovenerol Croat. 26:44–47. 2018.PubMed/NCBI
|
|
63
|
Pulitzer MP, Nolan KA, Oshman RG and
Phelps RG: CD30+ lymphomatoid drug reactions. Am J
Dermatopathol. 35:343–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Rogozea LM, Diaconescu DE, Dinu EA, Badea
O, Popa D, Andreescu O and Leaşu FG: Bioethical dilemmas in using
animal in medical research. Challenges and opportunities. Rom J
Morphol Embryol. 56:1227–1231. 2015.PubMed/NCBI
|
|
65
|
Purcaru D, Preda A, Popa D, Moga MA and
Rogozea L: Informed consent: How much awareness is there? PLoS One.
9:e1101392014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Dumitriu BO, Fasie V, Mardare N, Diaconu
C, Gurau G and Tatu AL: Formulation, preparation, physico-chimical
analysis, microbiological peculiarities and therapeutic challenges
of extractive solution of Kombucha. Rev Chim (Bucharest).
69:720–724. 2018.
|
|
67
|
Robu S, Chesaru BI, Diaconu C, Dumitriu
BO, Tutunaru D, Stanescu U and Lisa EL: Lavandula hybrida:
Microscopic characterization and the evaluation of the essential
oil. Farmacia. 64:914–917. 2016.
|
|
68
|
Nwabudike LC: Case reports of acne and
homeopathy. Complement Med Res. 25:52–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Nwabudike LC: Knowledge removes
discomfort. JAMA Dermatol. 154:738–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
